BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

CURRICULUM VITAE

Saswati Chatterjee
Division of Virology
City of Hope National Medical Center & Beckman Research Institute
1500 E. Duarte Road, Duarte, CA 91010.
Phone: 626-301-8436 (sec); 626-301-8906 (direct); Fax: 626-301-8458
schatterjee@coh.org

EDUCATION

1976	B.Sc., McGill University, Montreal, CANADA
1978	M.Sc., McGill University, Montreal, CANADA
1982	Ph.D., McGill University, Montreal, CANADA

RESEARCH EXPERIENCE

1997-Present	Associate Research Scientist, Division of Pediatrics, City of Hope National Medical Center. The use of AAV vectors for stem cell gene therapy. Biology of AAV vectors. Gene therapy of AIDS, cancer and cardiovascular diseases.
Dec 1991- 6/97	Assistant Research Scientist, Division of Pediatrics, City of Hope National Medical Center and Dept. of Molecular Genetics, Beckman Research Institute of the City of Hope, Duarte CA. Development of AAV vectors for gene transfer into hematopoietic stem cells. Gene therapy of AIDS and Cancer.
1990 - 1991	Assistant Professor, Visiting Scientist, Division of Molecular Virology & Immunology, Dept. of Microbiology, Georgetown University School of Medicine, Rockville, MD. Transduction of intracellular resistance to virus replication (HIV-1 & HSV-1) using adeno-associated virus (AAV)-based vectors.
1986 - 1990	Visiting Associate with Dr. James Rose, Laboratory of Viral Diseases (Dr B. Moss, Lab Chief), NIAID, NIH, Bethesda, MD. Research in Molecular Virology: Induction of intracellular resistance to immunodeficiency viruses via transducing eukaryotic viral vectors. Development of an AAV-based vector system for gene transductions. DNA replication mechanisms of AAV.
1985 - 1986	Research Fellow with Dr. Michael J. Rogers, Laboratory of Genetics, NCI, NIH, Bethesda, MD. Molecular Biology of the wild mouse Major Histocompatibility Complex.
1982 - 1985	Visiting Fellow with Dr. David H. Sachs Transplantation Biology Section, Immunology Branch, NCI, National Institutes of Health, Bethesda, MD. Immunochemistry and Immunogenetics of the murine Major Histocompatibility Complex.
1976 - 1982	Graduate research with Dr. P.K. Lala, Department of Anatomy, McGill University. The Immunobiology of Feto-maternal relationships.

1975 - 1976	B.Sc. project: Biochemical Genetics, with Dr. P. Hechtman, Dept. of Biology, McGill University and MRC Human Genetics Group.

TEACHING EXPERIENCE

1994-Present	City of Hope Graduate School faculty.
1980 - 1981	Gross Anatomy, Dept. of Anatomy, McGill University. Laboratory instructor to first year Medical students.
1980 - 1981	Surface Anatomy, Dept. of Anatomy, McGill University. Laboratory instructor to Physiotherapy Students
1979 - 1980	Medical Histology, McGill University. Laboratory instructor to first year Medical students.
1978 - 1979	Anatomy of the Head and Neck, Dept. of Anatomy, McGill University. Laboratory instructor to first year Dental students.
1972 - 1973	Mathematics - Teaching Assistant, Marianopolis College, Montreal.

HONORS & FELLOWSHIPS

1971 - 1973	Marianopolis College entrance and continuing scholarships
1973 - 1974	J.W. McConnell Scholarship in Science & Engineering, McGill University
1979	McGill University Faculty of Medicine Graduate Student Award
1979 - 1982	Conseil de la recherche scientifique du Quebec Graduate Studentship
1982	McGill University Dean's Honors' list
1982	Arthur W. Ham Graduate Student Award - Canadian Federation of Biological Societies.
1982	Mayo Foundation Fellowship.
1982	Medical Research Council Post Doctoral Fellowship.
1982 - 1985	Fogarty N.I.H. Visiting Fellowship.
1996	Moderator, oral presentation session on "Gene Therapy- Gene Transfer and Biology" American Society of Hematology 1996 annual meeting.
2001	Invited Faculty, American Society of Gene Therapy Annual meeting.

Manuscript Reviews:

Nature Medicine
Blood
Journal of Virology
Human Gene Therapy
Cancer Research
Journal of Immunotherapy
Pediatric Research
Biotechniques

COMMITTEES

1993	Ad Hoc Reviewer, National Heart Lung Blood Institute, NIH. In vitro expansion of Hematopoietic Stem Cells.
1994	Ad Hoc Reviewer, National Institute of Allergy and Infectious Diseases, NIH. RFA: AI-93-12. Immune Reconstitution of HIV infected Individuals.
1996	Ad Hoc Reviewer, National Institute of Diabetes, Digestive and Kidney Diseases, NIH. RFA: DK: 95-006. Pathogenesis and Treatment of Cystic Fibrosis.
1996	Reviewer: American Society of Hematology 1996 annual meeting - Gene Therapy- Gene Transfer and Biology
1996-Present	City of Hope Research Animal Care Committee.
1998	Special Emphasis Panel: PAR-97-080 - Novel HIV therapies: Integrated preclinical/clinical program, NIAID, NIH.
1998	Special Emphasis Panel: PAR-98-007 Innovative Grant Program for Approaches in HIV Vaccine Research, NIAID, NIH.
1998	Special Review Panel: Gene Therapy Center Cores. NIDDK, NIH.
1999	Reviewer: American Society of Gene Therapy. Abstracts for presentation at 1999 annual meeting.
2000	Special Emphasis Panel: ZDK1 GRB-2 (M1). Correction of Hepatocytes with recombinant AAV for correction of genetic and metabolic abnormalities. NIDDK, NIH
2001	Reviewer: American Society of Gene Therapy: Abstracts for presentation at 2001 annual meeting.

RESEARCH GRANT AWARDS

Saswati Chatterjee, Ph.D.

1/92-12/92	City of Hope Cancer Center Seed Grant Award. **AAV vector-mediated gene transfer into primary peripheral blood leukocytes and bone marrow cells.** S. Chatterjee, Principal Investigator.
1/92-12/92	City of Hope Biomedical Research Support Grant. **A comparison of transduction efficiencies of adeno-associated virus-based vector with retroviral vectors.** S. Chatterjee, Principal Investigator.
10/92-9/93	City of Hope Cancer Center Seed Grant Award. **Construction and use of an adeno-associated virus vector encoding the MDR-1 gene.** S. Chatterjee, Principal Investigator.
10/92-9/96	1P01CA 59308. **Gene Therapy of Marrow Cells**. J. Zaia, Principal Investigator. National Cancer Institute, NIH, Gene Therapy Program, Program Project Grant: Project 1: **AAV-mediated gene transfer into hemopoietic cells.** S. Chatterjee, Project Leader. Project 2: **AAV vector safety and regulatory issues**. S. Chatterjee, Co-investigator.
9/96-9/97	No cost extension of CA59308.
11/92-10/95	3U01AI25959. J. Zaia PI. National Institute of Allergy and Infectious Diseases, NIH; National Cooperative Drug Discovery Grants (NCDDG) for the treatment of HIV Infection. Project: **Anti-SIV gene therapy in Rhesus Monkeys**. S. Chatterjee, Co-Investigator.
7/96-5/99	1R01AI40001. **Multivalent AAV vectors for HIV-1 gene therapy.** S. Chatterjee, Principal Investigator. National Institute of Allergy and Infectious Diseases, NIH. $540,014.
6/99-5/00	No cost extension of AI40001.
9/97-9/00	1R01CA75186. **Gene modified dendritic cells for tumor immunotherapy.** S. Chatterjee, Principal Investigator. National Cancer Institute, NIH. $685,475.
10/00-9/02	No cost extension of CA75186.
7/99-6/04	1PO1HL60898-01A1. **Gene therapy approaches for blood and vascular diseases**. KK Wong, Principal Investigator. National Heart, Lung, Blood Institute, NIH. $7,262,996 **Project 1: AAV Transduction of quiescent hematopoietic stem cells.** S. Chatterjee, Project leader. $1,040,014 direct cost. **Core B: Vector Core**. S. Chatterjee, Core leader. $928,159 direct cost.
4/00-3/03	1P01CA30206-19. Bone Marrow Transplantation for Hematologic malignancies. SJ Forman, Principal Investigator. Project IV. S. Chatterjee, Co-Investigator. $214,859 direct cost.

9/99-8/04	NIAID-DAIT-BAA-99-12.. Clinical Trials and Clinical markers of Immunologic Diseases. H. Oppenshaw, Principal Investigator; S. Chatterjee, Co-Investigator.
10/99-9/04	NIAID-DAIT-BAA-99-31. National Collaborative Study of Stem Cell Transplanatation for Autoimmune Disease. H. Oppenshaw, Principal Investigator; S. Chatterjee, Co-Investigator.

PATENTS & LICENSES

12/12/95	US Patent No.: 5,474,935. Saswati Chatterjee & K.K. Wong Jr.: **Adeno-associated virus (AAV)-based eukaryotic vectors**.
6/95	**AAV packaging cell lines.** Licensed by Applied Immune Sciences, San Jose, CA.
12/97	**Adeno-associated virus (AAV)-based eukaryotic vectors & AAV packaging cell lines**. Licensed by Strata Biosciences, Alameda, CA.

BIBLIOGRAPHY

1. **Chatterjee, S.** and Hechtman, P.: t-aminobutyric acid metabolism in brain homogenates of the spastic mouse. Biochem.Gen. 15: *1147-151*, 1977.

2. **Chatterjee S.**: Placental H-2 antigens and changes in the maternal lymphoid system during allogeneic pregnancy in the mouse. M.Sc. Thesis, McGill University, 1978.

3. **Chatterjee, S.**, and Lala, P.K.: The localization of H-2 antigens on mouse trophoblast cells. J. Exp. Med. 149: *1238-1253*, 1979.

4. **Chatterjee, S.**, Santer, V., and Lala, P.K.: Changes in maternal small lymphocyte subsets during allogeneic pregnancy in the mouse. Cell. Immunol. 50: *290-304*, 1980.

5. **Chatterjee, S.** and Lala, P.K.: MHC antigens on mouse trophoblast cells: absence of Ia antigens despite the presence of H-2K and D. J. Immunol. 127: *2070-2073*, 1981.

6. **Chatterjee S.**, and Lala, P.: Localization of paternal H-2K antigens on murine trophoblast cells in vivo. J. Exp. Med. 155: *1679-1689*, 1982.

7. **Chatterjee, S.**: The immunobiology of feto-maternal relationship. Ph.D. Thesis, McGill University, 1982.

8. **Chatterjee, S.**, Montgomery, B., and Lala, P.K.: Alloantigenicity of trophoblast cells. Amer. J. Reprod. Immunol. 3: *127-131*, 1983.

9. Lala, P.K., **Chatterjee, S.**, and Montgomery, B.: Major histocompatibility antigens on murine and human

trophoblast cells. Transplant. Proc. 15: *883-886*, 1983.

10. Lala, P.K., **Chatterjee, S.**, Kearns, M., Montgomery, B., and Colavincenzo, V. Immunobiology of the Feto-Maternal Interface. Immunol. Rev. 75: *87-116*, 1983.

11. **Chatterjee, S.**, Parhar, R. and Lala, P.K.: An Evaluation of the Maternal Natural Killer Cell Population during the course of Murine Pregnancy. Cell Immunol. 84: *264-275*, 1984.

12. Bluestone, J.A., Potter, T.A., **Chatterjee, S.**, and Rajan, T.V.: CTL recognize different determinants from those defined serologically on L^d somatic cell mutants. J.Immunol. 133:*1168-1173*, 1984.

13. **Chatterjee S.**, Berg, S.K. and Sachs, D.H.: Molecular and serologic analysis of products of the D-region of $H\text{-}2^q$. Transplant. Proc. 17: *722-724*, 1984.

14. **Chatterjee, S.**, Schlauder, G., Sachs, D.H., Glimcher, L.H., Paul, W.E., and McKean, D.J.: A biochemical analysis of $I\text{-}A^k$ molecules from mutant antigen presenting cell lines. Immunogenetics 23: *121-125*, 1986.

15. **Chatterjee, S.**, Lillehoj, E., Hernandez, D.M., Coligan, J.E. and Sachs, D.H.: Analysis of the D-region products of H-2q using monoclonal antibodies reveals the expression of a new class 1-like molecule. Immunogenetics 25: *7-14*, 1987.

16. Rabinowitz, R., Sharrow, S.O., **Chatterjee, S.**, Rogers, M.J., and Sachs, D.H.: Qa alloantiantigen expression on functional T lymphocytes from spleen and thymus. Immunogenetics 24: *391-401*, 1987.

17. **Chatterjee, S.**, Wong K.K., Rose J.A. and Johnson, P.R. : Transduction of intracellular resistance to HIV production by an adeno-associated virus-based antisense vector. *In* Vaccine 91: Modern approaches to new vaccines including the prevention of AIDS. R.M. Channock, H.S. Ginsberg, F. Brown and R.A.Lerner Eds. Pp 85-90. Cold Spring Harbor Laboratory Press. 1991.

18. Wong K.K., Rose J.A. and **Chatterjee, S.**: Restriction of HSV-1 production in cell lines transduced with an antisense viral vector targeting the ICP4 gene. *In* Vaccine 91: Modern approaches to new vaccines including the prevention of AIDS. R.M. Channock, H.S. Ginsberg, F. Brown and R.A.Lerner Eds. Pp 183-189. Cold Spring Harbor Laboratory Press. 1991.

19. Wong K.K. and **Chatterjee, S.**: Controlling herpes simplex virus (HSV) infections: Intracellular immunization, the way of the future? Current Topics in Microbiology and Immunology , B. Rouse, Editor. Springer Verlag 179: *159-174*, 1992.

20. **Chatterjee, S.**, Johnson, P.R. and Wong, K.K.: Dual target inhibition of HIV-1 in vitro with an adeno-associated virus-based antisense vector. Science, 258: *1485-1488*, 1992.

21. Zaia, J.A, **Chatterjee, S.**, Wong, K.K., Elkins, D., Taylor, N.R. and Rossi, J.J.: Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy. *In* Antisense Strategies. The Annals of the New York Academy of Sciences, 660: *95-106*, 1992.

22. **Chatterjee, S.** and Wong, K.K. Adeno-associated viral vectors for the delivery of antisense RNA. Methods: A Companion to Methods in Enzymology. 5: *51-59*, 1993.

23. Podsakoff GM, Wong KK and **Chatterjee, S**. Stable and efficient gene transfer into non-dividing cells by adeno-associated virus-based vectors. J. Virol. 68: *5656-5666,* 1994.

24. Lu, D, **Chatterjee S**, Brar, D, and Wong KK. Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. Cancer Gene Therapy, 1:*267-277*, 1994.

25. **Chatterjee S,** Wong KK, Lu D, Permana PA and Podsakoff GM. Novel approaches for efficient gene transfer into hematopoietic progenitor cells: the use of adeno-associated virus vectors. Bone Marrow Transplantation, 15: *S309-S313*, 1995.

26. **Chatterjee S**, Lu D, Podsakoff GM, Wong, KK. Strategies for efficient gene transfer into hematopoietic cells: The use of adeno-associated virus vectors in gene therapy. The Annals of the New York Academy of Sciences. 770: *79-90*, 1995.

27. Shaughnessy, E, Lu D, **Chatterjee S**, and Wong, KK. Parvoviral vectors for the Gene Therapy of Cancer. Seminars in Oncology 23: *159-171*, 1995.

28. **Chatterjee S** and Wong, KK. Adeno-associated virus vectors for gene therapy of the hematopoietic system. Current Topics in Microbiology and Immunology., Giraud and Berns Ed. Springer Verlag 218: *61-73*, 1996.

29. Wong KK and **Chatterjee S**. Adeno-associated virus vectors as antivirals. Current Topics in Microbiology and Immunology. Giraud and Berns Ed. Springer Verlag 218: *145-170*, 1996.

30. Fisher-Adams G, Wong, KK, Podsakoff GM, Forman, SJ and **Chatterjee S**. Integration of adeno-associated virus vector genomes in Human CD34 cells following transduction. Blood, 88: 492-504, 1996.

31. Bertrand E, Castanotto D, Zhou C, Carbonelle C, Lee NS, Good P, **Chatterjee S,** Grange T, Pictet R, Kohn D, Engelke D and Rossi J. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA, 3: 75-88, 1997.

32. Margolin K, Negrin RS, Wong KK, **Chatterjee S** and Forman SJ. Cellular immunotherapy and autologous transplantation for hematologic malignancies. Immunol. Rev. 157: 231-240,1997.

33. Wong KK, Shaughnessy E, Lu D, Fisher-Adams G and **Chatterjee S**. Parvovirus Vectors for the Gene Therapy of Cancer. *In* Gene Therapy of Cancer. E. Lattime and S. Gerson Eds. Academic Press. 1998.

34. **Chatterjee S**, Li W, Wong C, Lu D, Fisher-Adams G, Guha M, Macer J, Forman SJ and Wong KK. Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vector. Blood. 93:1882-1894, 1999.

35. Mi J, **Chatterjee S,** Wong KK, Forbes C, Lawless G, Tobin AJ. Recombinant adeno-associated virus drives constitutive production of glutamate decarboxylase in nueral cell lines. J Neuroscience Research, 57: 137-149, 1999.

36. **Chatterjee S** and Wong KK. Adeno-associated virus vectors for the delivery of ribozymes. *In* "Intracellular

Ribozyme Applications: Principles and Protocols." JJ Rossi and L Couture Eds. pp189-215, Horizon Scientific Press. 2000.

37. Wong KK and **Chatterjee S**. Parvovirus Vectors for the Gene Therapy of Cancer. *In* Gene Therapy of Cancer. Second Edition, E. Lattime and S. Gerson Eds. Academic Press. 2001. *In Press.*

38. Sun J, Krouse RS, Forman SJ, Senitzer D, Sniecinski I, **Chatterjee S** and K.K. Wong Jr. Immunogenicity of a P210BCR-ABL Fusion Domain Candidate DNA Vaccine Targeted to Dendritic Cells by an rAAV Vector In Vitro. Blood. *In Review.*

37. Wong CA, Li W, Forman SJ, Wong KK, **Chatterjee S**. Gene transfer into quiescent CD34+CD38- hematopoietic progenitor cells in G0 with adeno-associated virus vectors. *In preparation.*

38. Fisher-Adams G, Wong KK and **Chatterjee S**. Long term transcriptional potentials of genes encoded by integrated AAV vectors in transduced cell lines. *In preparation.*

39. Li LJ, Brar D, Permana P, Rossi JJ, Wong KK and **Chatterjee S** . Promoter strengths and orientation dependance of transgene expression from multivalent AAV vectors. *In preparation.*

40. Li LJ, Rossi JJ, Forman SJ , Wong KK and **Chatterjee S**. Long term inhibition of HIV-1 replication in progeny macrophages derived from CD34+ hematopoietic progenitor cells transduced with AAV vectors encoding anti-HIV genes. *In preparation.*

41. Wong KK, Rosborough E, Aye T and **Chatterjee S**. Permanent packaging cell lines for the production of adeno-associated virus vectors. *In preparation.*

ABSTRACTS & PRESENTATIONS.

1. **Chatterjee, S.**: Localization of major histocompatibility antigens on mouse trophoblast cells. Anat. Rec. 193: 502-503, 1979.

2. **Chatterjee, S**. and Lala, P.K.: Localization of mouse trophoblast cells. Fed. Proc. 38:929,1979.

3. **Chatterjee, S.**, and Lala, P.K.: Characterization of maternal small lymphocyte subsets during allogeneic pregnancy. Proc. Can. Fed. Biol. Soc. 1979.

4. **Chatterjee, S.**, and Lala, P.K.: Ia antigens on mouse trophoblast cells. Proc. Can. Fed. Biol. Soc., 1980.

5. **Chatterjee, S.**, and Lala, P.K.: MHC antigens on mouse trophoblast cells. Presented at the Fourth International Congress of Immunology, Paris and 7th International Convocation on Immunology: Immunobiology of the Major Histocompatibility Complex, Buffalo, NY, USA, 1980.

6. **Chatterjee, S.**, and Lala, P.K.: Surface marker analysis of maternal T lymphocyte subsets during pregnancy. International Conference on Reproductive Immunology, Banff, Alberta, Canada. J.Reprod.Immunol.,Suppl. S25, 1981.

7. **Chatterjee, S.**, and Lala, P.K.: Natural killer cell activity during murine pregnancy. International Conference on Reproductive Immunology, Banff, Alberta, Canada. J.Reprod. Immunol. Suppl. S24, 1981.

8. **Chatterjee, S.**, and Lala, P.K.: Surface marker characterization of maternal T lymphocyte subsets during pregnancy. Proc. Can. Fed. Biol. Soc. 24: 140, 1981.

9. **Chatterjee, S.**, and Lala, P.K.: In situ localization of H-2K antigens. Fed. Proc. 41(3): 426, 1982.

10. **Chatterjee, S.**, and Lala, P.K.: In vivo localization of H-2K antigens. Fed. Proc. 41(3): 426, 1982.

11. Lala, P.K., and **Chatterjee, S.**: A comparison of host natural killer cell responses during tumour-bearing and pregnancy. Proc. Can. Fed. Biol. Soc. 24: 140,1982.

12. **Chatterjee, S.**, and Lala, P.K.: In situ localization of paternal H-2K antigens on trophoblast cells. Amer. J. Reprod. Immunol. 2(3): 170, 1982.

13. Lala, P.K., **Chatterjee, S.**, and Montgomery, B.: Major histocompatibility antigens on murine and human trophoblast cells. Proc. IX Intl. Congress Transplant. Soc., Brighton, U.K., 1982.

14. **Chatterjee, S.**, Hernandez, D.M., and Sachs, D.H.,: An immunochemical analysis of the products of the D region of H-2^q. Fed. Proc. 42: 1370, 1983.

15. Glimcher, L., **Chatterjee, S.**, Schlauder, G., Paul, W.E., and McKean, D.J.: Functional Ia mutant antigen presenting cell lines. Fed. Proc. 43: 1733, 1984.

16. Schlauder, G., Beck, B.,Bell, M., Chase, C., **Chatterjee, S.**, Glimcher, L., Paul, W., Pierres, M., Sachs, D. H., and McKean, D.J.: Biochemical characterization of mutant I-A^k molecules from antigen presenting B cell - B lymphoma hybridomas. Fed. Proc. 43: 1599, 1984.

17. **Chatterjee, S.**, Hernandez, D.M. and Sachs, D.H.: An analysis of the antigens encoded by the D - region of H-2^q. 10th Ann. Cong. Transplant. Soc., Minneapolis, 1984.

18. Rogers, M.J., **Chatterjee, S.** and Siwarski, D.F.: Sequences of class I genes from Mus Pahari: implications for the evolution of a multi-gene family. Prog. in Immunol. VI. 1986.

19. **Chatterjee, S.**, Sebring, E., Rose, J.: AAV virions contain genomes that are processed at or near the DNA origin. Presented at the American Society for Virology, June 12-16,1988, Austin, Texas.

20. **Chatterjee,S.**, Wong, K.K. Jr., Rose, J.A. and Johnson, P.R.: Establishment of intracellular resistance to human immunodeficiency virus replication. Cold Spring Harbor Meeting: RNA Tumour Viruses, NY., May 23-25, 1990.

21. **Chatterjee, S.**, Johnson, P.R. and Wong, K.K. Jr.: Transduction of intracellular resistance to HIV production by an adeno-associated virus-based antisense vector. Cold Spring Harbor Meeting: Modern Approaches to New Vaccines Including the Prevention of AIDS, NY, September 12-16, 1990.

22. Wong. K.K., Rose, J., **Chatterjee, S.**: Restriction of HSV-1 replication in cell lines transduced with an antisense viral vector targeting the HSV-1 ICP4 gene. Cold Spring Harbor Meeting: Modern Approaches to New Vaccines , NY, September 12-16, 1990.

23. **Chatterjee, S.** and Wong, K.K. : Transduction of intracellular resistance to virus replication using adeno-associated virus-based vectors. The Second International Conference on Catalytic RNA as anti-HIV agents: Design and Delivery, San Diego, CA, October 21-24, 1990.

24. Wong, K.K., Rose J. A. and **Chatterjee, S.**: Inhibition of herpes simplex virus type 1 (HSV-1) production in cell lines transduced with an adeno-associated virus based antisense vector targeting the requisite ICP4 gene. The Second International Conference on Catalytic RNA as anti-HIV agents: Design and Delivery, San Diego, CA, October 21-24, 1990.

25. KK Wong and **S Chatterjee**. Establishment of intracellular resistance to HSV-1 production in cells transduced with an adeno-associated virus based antisense vector. J. Cell. Biochem. Supp 16F: 52, 1992.

26. **Chatterjee, S.**, and Wong, KK.: Transduction of intracellular resistance to HIV by an adeno-associated virus-based antisense vector. J. Cell. Biochem. Supp 16F: 58, 1992.

27. **Chatterjee, S.**, Forman, S., Zaia, J., Wong. K.K.: An adeno-associated virus-based dual-target antisense vector: High efficiency inhibition of HIV-1 and transduction of primary hemopoietic cells. Cold Spring Harbor Meeting: Gene Therapy, NY, September 22-26, 1992.

28. Wong. K.K. and **Chatterjee, S.** Transduction of intracellular resistance against HIV utilizing an adeno-associated virus-based vector: potential for antiviral gene therapy. 32nd Annual ICAAC Meeting, Anaheim, October 11-14, 1992.

29. **Chatterjee, S.**, Wong, K.K., Podsakoff, G., Zaia, J., Forman, S. Adeno-associated virus vectors for high efficiency gene transfer into primary human hematopoietic cells. American Society of Hematology. Blood 80: Suppl 1, 167A, 1992.

30. **Chatterjee, S.**, Podsakoff, G., Wong K.K. Strategies for antiviral gene therapy: Use of an Adeno-associated virus (AAV)-based vector system to confer intracellular resistance to targeted viruses. Third International Symposium on catalytic RNAs (ribozymes) and targeted gene therapy for the treatment of HIV infection. Invited talk at San Diego, December 6-11, 1992.

31. **Chatterjee S**, Podsakoff, G.M. and Wong K.K.: A Gene Therapeutic Approach to AIDS: Adeno-Associated Virus Vectors for the Delivery of Genes Encoding Antisense RNA and Ribozymes Targeting HIV-1. Invited talk for Coordinated Therapies for HIV-1 Infection. Washington DC, July 1993.

32. **Chatterjee S**, Podsakoff, G.M. and Wong K.K.: Adeno-associated virus vectors for the delivery of anti-HIV genes. Invited talk for Symposium on Genetic Therapies for HIV-1 Infection. , p 441, 33rd ICAAC Meeting, New Orleans, LA, October, 1993.

33. Wong, K.K., Podsakoff, G., Lu, D. and **Chatterjee, S.** High efficiency gene transfer into growth arrested cells utilizing an adeno-associated virus-based vector. Blood *82*, Suppl.1, 302a,1993

34. Snyder, D., Wu Y., Wong, K.K., **Chatterjee, S.** and Forman, S.J. Ribozyme-viral vector constructs inhibit BCR-ABL gene expression in Philadelphia-chromosome positive cell lines. Blood *82*, Suppl.1, 40, 1993.

35. Shaughnessy, E., Wong, K.K. and **Chatterjee, S.** Adeno-associated virus-based vectors: Biology and potential role in the gene therapy of cancer. Cancer Gene Therapy, *1*, Suppl. 1, 9,1993.

36. **Chatterjee S** Adeno-associated virus: a high efficiency vector for gene therapy. Invited talk for Keystone Symposia on Controversies on Bone Marrow Transplantation. January, 1994.

37. **Chatterjee S,** Wong KK, Podsakoff G, Lu D, Permana P and Brar D. Strategies for anti-HIV gene therapy: the use of adeno-associated virus vectors. Invited talk for UCLA AIDS Symposium, Palm Springs, CA, March 3-6, 1994.

38. Permana P, Wong KK, Brar D and **Chatterjee S.** Transcription of anti-HIV RNA from adeno-associated virus vectors encoding RNA polymerase II- and III-dependent promoters. Poster session. UCLA AIDS Symposium, Palm Springs, CA, March 3-6, 1994.

39. Shaughnessy, E., Wong, K.K., Podsakoff, G, Kane, S and **Chatterjee, S.** Adeno-associated virus vectors for MDR-1 gene therapy. Proc. Amer. Assoc. for Cancer Research *35*, 373, 1994.

40. Lu, D, **Chatterjee, S**, Brar, D and Wong KK. High efficiency in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16 mediated by ribozymes transcribed from an adeno-associated virus vector. Proc. Amer. Assoc. for Cancer Research 35, 309, 1994.

41. **Chatterjee S**, Wong KK Jr, Podsakoff G, Shaughnessy E. Gene transfer into human hematopoietic progenitor cells by adeno-associated virus vectors for the treatment of malignancies. Third International Conference on the Gene Therapy of Cancer, Coronado, CA; November 10-12; Cancer Gene Therapy 1:323 (III-59), 1994.

42. Brar D, Wong KK Jr, Permana P, **Chatterjee S**. Promoter interactions in adeno-associated virus vectors encoding multiple gene cassettes: potential use in anti-oncogene vector design. Third International Conference on the Gene Therapy of Cancer, Coronado, CA; November 10-12, Cancer Gene Therapy 1:321 (V-53), 1994.

43. Wong KK, Brar D, Rossi J, **Chatterjee, S.** Primary human CD34+ peripheral blood stem cells (PBSCs) are efficient targets for adeno-associated virus vector-mediated gene transfer: Prospects for anti-AIDS genetic intervention. Blood, 84, Supplement 1, 743a; Nov 15, 1994. American Society of Hematology Meeting December 2-6, 1994, Nashville, Tenn. No.2957.

44. Podsakoff G, Shaughnessy EA, Lu D, Wong KK Jr, **Chatterjee S.** Long term in vivo reconstitution with murine marrow cells transduced with an adeno-associated virus vector. Blood, 84, Supplement 1, p. 256a; Nov 15, 1994. American Society of Hematology Meeting December 2-6, 1994, Nashville, Tenn. No.1009

45. **Chatterjee S**, Podsakoff G, Wong KK Jr. Gene transfer into terminally differentiated primary human peripheral blood-derived mononuclear cells by adeno-associated virus. *Blood*, 84, Supplement 1, p360a; Nov 15, 1994. American Society of Hematology Meeting December 2-6, 1994, Nashville, Tenn. No.1424.

46. Lu D, Wong KK Jr, Podsakoff G, **Chatterjee S**. Stable and efficient adeno-associated virus-mediated gene transfer into primitive human marrow-derived hematopoietic cells in long term culture. Blood, 84, Supplement 1, p.360a; Nov 15, 1994. American Society of Hematology Meeting December 2-6, 1994, Nashville, Tenn. No.1425.

47. Wong KK, Lu D, Podsakoff G, Brar D, **Chatterjee S**. Efficient Gene Transfer to Primary Human CD4+ T Lymphocytes, Monocyte-macrophages, and CD34+ Hematopoietic Stem Cells Mediated by Adeno-associated Virus-based Vectors: Prospects for the Gene Therapy of AIDS. Second National Conference of Human Retroviruses and Related Infections, Washington, DC. January 29-February 2, 1995

48. **Chatterjee S**, Podsakoff G, Lu D, Shaughnessy E, Fisher-Adams, G, Hegyi, E, and Wong KK. Strategies for efficient gene transfer into hematopoietic cells: The use of adeno-associated virus vectors in gene therapy. Symposium on Stem Cells: Prospects for the Clinic. J Mule & J Larrick, organizers. Palo Alto, CA, February 6-7, 1995.

49. Ho JL, Wong KK, Primus FJ, Fisher-Adams G, **Chatterjee S**, Slovak ML. Contribution of fluorescence *in situ* hybridization (FISH) to gene therapy research. American Cytogenetics Conference, San Diego, CA, 1995.

50. Wong KK Jr, Fisher-Adams G, Shaughnessy E, Lu D, **Chatterjee S**. Adeno-associated virus gene delivery to hematopoietic stem cells. Second European Conference on Gene Therapy of Cancer. September 7 & 8, 1995. King's College, Strand, London.

51. **Chatterjee S**, Lu D, Shaughnessy E, Fisher-AdamsG, Podsakoff G and KK Wong. Efficient transduction of primary hematopoietic cells by adeno-associated virus vectors. VIth International Parvovirus Meeting, Montpellier, France, September 1995.

52. Fisher-Adams G, Wong K.K. and **Chatterjee, S**. Stable integration of rAAV vector sequences into transformed and primary cells. VIth International Parvovirus Meeting, Montpellier, France, September 1995.

53. Wong, Jr. K.K. , Lu, Di, Brar, Deepinder, Rossi, John, **Chatterjee, S**. AAV Vectors as antivirals. VIth International Parvovirus Meeting, Montpellier, France, September 1995.

54. **Chatterjee S**, Lu D, Shaughnessy E, Fisher-Adams G, Podsakoff G, E Rosborough, Li L and Wong Jr K.K. Efficient transduction of primitive hematopoietic progenitor cells by adeno-associated virus vectors. Blood 86, Supplement 1, p412a.1995.

55. Fisher-Adams G, Wong Jr. KK and **Chatterjee S**. Stable integration of rAAV vector sequences into transformed and primary cells. Blood 86, Supplement 1, p412a.1996.

56. Shaughnessy E, Wong KK, Podsakoff G , Kane S and **Chatterjee S**. Gene transfer of MDR1 into primary human CD34+ enriched marrow cells mediated by an adeno-associated virus vector. Blood 86, Supplement 1, p244a.1996.

57. **S Chatterjee**, Fisher-Adams G , Lu D, Shaughnessy E, Li L, Rossborough E and K.K. Wong Jr. AAV vectors for gene transfer into unstimulated hematopoietic cells. NIDDK workshop on AAV Vectors: Gene transfer into quiescent cells. NIDDK, NIH, Bethesda, MD, December, 1995.

58. Guha M, Fisher-Adams G, Wong KK and **Chatterjee S**. Modulation of chromosomal integration of adeno-

associated virus vectors in CD34 cells. Annual Society of Hematology, Orlando, FL, Dec 1996.

59. Shaughnessy EA, **Chatterjee S** and Wong KK. Characterization of an MDR1 mutation which results in the dissociation of rhodamine 123 exclusion and cellular resistance to colchicine and paclitaxel. Annual Society of Hematology, Orlando, Fl, Dec 1996.

60. Konkal-Matt R. Prasad, Permana P, Wong KK, **Chatterjee S**. Adeno-associated virus Antisense and Ribozyme Vectors for HIV Gene Therapy.SPIRAT/NCDDG HIV Conference, Vienna VA. June 1997.

61. Wong KK, Fisher-Adams G., Lu D; Li L, Prasad KMR, Rossi J, Zaia J, **Chatterjee S**. Gene transfer to hematopoietic cells with rAAV vectors. SPIRAT/NCDDG HIV Conference, Vienna VA. June 1997.

62. **Chatterjee S**, Fisher-Adams G, Li C W, Guha M and Wong KK. AAV vector integration in human hematopoietic progenitor cells. International Parvovirus Workshop, Heidelberg, Germany, September, 1997.

63. Wong KK, Shaughnessy EA, Juty N, **Chatterjee S**. Transfer of the MDR1 gene into primary murine and human hematopoietic progenitors mediated by an rAAV vector. International Parvovirus Workshop, Heidelberg, Germany, September, 1997.

64. Wang L, Pan T, Ong J, **Chatterjee S**, Wong KK, Shah PK. rAAV vectors encoding Apo A-1 and Apo A-1 Milano for gene therapy of atherosclerosis. International Parvovirus Workshop, Heidelberg, Germany, September, 1997.

65. Li CW, Lu D, Wong KK, **Chatterjee S**. Transduction of primary human CD34+ progenitors in long term culture by an rAAV vector. American Society of Hematology, San Diego, December 1997.

66. Li L-J, Wong KK, **Chatterjee S**. Efficient transduction and expression of CD34+ hematopoietic progenitors and macrophages with multivalent AAV vectors encoding anti-HIV-1 genes. American Society of Hematology, San Diego, December 1997.

67. Rosborough E, Shaughnessy EA, Li W, Li L-J, Fisher-Adams G, Podsakoff GM, **Chatterjee S**, Wong KK. Gene transfer into multipotential self renewing murine hematopoietic progenitor cells by AAV vectors. American Society of Hematology, San Diego, December 1997.

68. Wong KK, Rosborough E, Shaughnessy EA, Li W, Li LJ, Fisher-Adams G, **Chatterjee S**. Analysis of hematopoietic and nonhematopoietic tissues following transplantation with rAAV vector transduced murine marrow progenitors. American Society of Gene Therapy, Seattle, WA, May 28-31, 1998.

69. Krouse RS, Wong KK, Sniecinski I, Forman SJ, **Chatterjee S**. Adeno-associated virus vector-mediated gene transfer into peripheral blood-derived dendritic cells. American Society of Gene Therapy, Seattle, WA, May 28-31, 1998.

70. **Chatterjee S**, Li LJ, Li W, Wong C, Fisher-Adams G, Forman SJ, Zaia JA, Rossi J, Wong KK. Protection from HIV challenge in macrophages derived from CD34+ marrow cells transduced with AAV-based anti-HIV vectors. American Society of Gene Therapy, Seattle, WA, May 28-31, 1998.

71. Fisher-Adams G, Wong KK, **Chatterjee S**. Long Term Transcriptional Potentials of Transgenes Encoded by

AAV Vectors. American Society of Gene Therapy, Seattle, WA, May 28-31, 1998.

72. Juty N, Shaughnessy EA, **Chatterjee S**, Wong KK. Recombinant Adeno-associated Virus Vector Mediated Gene Transfer of MDR1 into Human Hematopoietic CD34+ Cells. American Society of Gene Therapy, Seattle, WA, May 28-31, 1998.

73. Wong CA, Li W, Forman SJ, Wong KK, **Chatterjee S**. Gene transfer into quiescent CD34+CD38- hematopoietic progenitor cells with adeno-associated virus vectors. American Society of Hematology, Blood 92: 664a, 1998.

74. Krouse RS, Forman SJ, Wong KK, **Chatterjee S**. rAAV vector transduction of dendritic cells for development of tumor-specific vaccines. American Society of Hematology, Blood 92:146a, 1998.

75. Wong CA, Li W, Forman SJ, Wong KK, **Chatterjee S.** Transduction of Quiescent CD34+CD38- Human Hematopoietic Progenitor Cells in G0 with Adeno-associated Virus Vectors. American Society of Gene Therapy. Molecular Therapy: 1: S94. 2000

76. Wong CA, Wong ,K.K. Li W, Tager L, Forman SJ, **Chatterjee S** Long-term In Vivo Multilineage Hematopoietic Engraftment of NOD/SCID Mice with rAAV-Transduced Human Cord Blood CD34+CD38- Cells. American Society of Gene Therapy. Molecular Therapy: 1: S105. 2000.

77. Sun J, Forman SJ, Sniecinski I, Senitzer D, **Chatterjee S** and Wong K.K. Jr. Immunogenicity of a P210BCR-ABL Fusion Domain DNA Vaccine Candidate Targeted to Dendritic Cells by an rAAV Vector In Vitro. American Society of Gene Therapy. Molecular Therapy: 1: S260. 2000.

78. Wong CA, Li W, Forman SJ, Wong KK, **Chatterjee S.** rAAV transduction of quiescent CD34+++CD38- human hematopoietic progenitor cells residing in the G0 phase of the cell cycle. International Parvovirus Workshop, Mont Tremblant, Quebec, Canada. June, 2000.

79. Wong CA, Wong ,K.K. Li W, Tager L, Forman SJ, **Chatterjee S**. In vivo multilineage hematopoietic reconstitution of nod/scid mice with rAAV transduced human cord blood CD34+CD38- cells. International Parvovirus Workshop, Mont Tremblant, Quebec, Canada. June, 2000.

80. **S. Chatterjee**. RAAV vectors in vivo. American Society of Gene Therapy. Seattle 2001.

MAJOR INVITED TALKS

The Third International Symposium on Catalytic RNAs and Targeted Gene Therapy for the treatment of HIV infection. San Diego, December 6-11, 1992.

Coordinated Therapies for HIV-1 Infection. Washington DC, July 11-16,1993.

Symposium on Genetic Therapies for HIV-1 Infection. American Society for Microbiology, 33rd ICAAC Meeting, New Orleans October, 1993.

Keystone Symposia: Controversies on Bone Marrow Transplantation. Keystone, CO, January 23-30, 1994.

UCLA AIDS Symposium, Palm Springs, CA, March 3-6, 1994.

Symposium on Stem Cells: Prospects for the Clinic. J Mule & J Larrick, organizers. Palo Alto, CA, February 6-7, 1995.

New York Academy of Sciences Symposium on Bone Marrow Transplantation: Foundations for the 21st century. Orlando, FL, March 15-18, 1995. Robert Sackstein, organizer.

Hemopoietic Stem Cell Gene Therapy. Chevy Chase, MD. September 28-October 1, 1995. G. Stamatoyanopoulos, organizer.

AAV vectors: Gene transfer into quiescent cells. Bethesda, MD December 6, 1995. C. McKeon, RJ Samulski, organizers NIDDK, NIH.

AAV vectors for Gene Transfer into Stem Cells. Invited presentation to the Scientific Board of Systemix, Palo Alto CA, March 8, 1996.

FDA Gene Therapy Conference. July 11-12, 1996. Robert Anderson, Center for Biologics Evaluation and Research, FDA & Biological Resources Branch, NCI, NIH, organizer.

American Society of Hematology 1996 annual meeting. Moderator, oral presentation session on "Gene Therapy: Gene Transfer and Biology".

Annual Symposium on Gene Medicine. June 13, 1997. William McBride and James Economou, organizers. UCLA, Los Angeles, CA.

Principal Investigators Meeting, NHLBI, NIH, Rockville MD, July 6-7,2000. Sonia Skarlatos, organizer.

Symposium on Cardiovascular Gene Therapy 2000. September 21, 2000. PK Shah & T. Rajavashisth, organizers, Cedars Sinai Medical Center.

Annual Meeting of the American Society of Gene Therapy. Workshop on AAV vectors.. rAAV vectors in vivo. May 2001, Seattle, WA.

Analysis of CD34 cells subpopulations from OM. Shows that CD34+CD38- cells are in G0.

FIGURE 1


Engraftment of human CB CD34+38-cells in BM of NOD/SCID mice
▲ Transplanted with 3-4 X 104 CD34+CD38- CB cells
■ Transplanted with 6-8 X104 CD34+CD38- CB cells
— Mean level of engraftment per interval
% human CD45+ cells
100%
80%
60%
40%
20%
0%
8-10 WK
12-15 WK
16-18 WK
22-25 WK
weeks post transplantation


Incidence of huCD45+ cells in the spleens of transplanted NOD/SCID mice
▲ Transplanted 3-4 X 104
■ Transplanted 4-6 X 104
Mean level of engraftment
100%
80%
60%
40%
20%
0%
% human CD45+ cells
8-10 wk
12-15 wk
16-18 wk
22-25 wk
weeks post transplantation

FIGURE 2

FIGURE 3


Percentage of hematopoietic lineage committed cells within the bone marrow CD45+ population of NOD/SCID mice
BMCD34+ progenitor
BMCD14+ myeloid
BMCD19+ B lymphoid
% of human lineage subset within CD45+ population in E
100%
80%
60%
40%
20%
0%
8-10 wk
12-15 wk
16-18 wk
22-25 wk
weeks post transplantation

Weeks Post Transplant	Bone Marrow CD34+	CD14+	CD19+	Spleen CD19+
9-10	75% (3/4)	100% (4/4)	50% (2/4)	25% (1/4)
12-15	57% (4/7)	50% (3/6)	50% (3/6)	67% (4/5)
17-18	43% (3/7)	57% (4/7)	57% (4/7)	43% (3/7)
22-25	75% (3/4)	67% (2/3)	33% (1/3)	33% (1/3)
Total	**59% (13/22)**	**65% (11/17)**	**53% (9/17)**	**53% (9/17)**

TABLE 1

FIGURE 4


% vector positive colonies
100%
80%
60%
40%
20%
0%
8-10 wk
12-15 wk
16-18 wk
21-25 wk
weeks post transplantation

cont'd

Stained the rest of the CD34+ cells w/ Hoechst & Pyronin to sort for G_0 and G_1 populations.



Bone Marrow sample today! 15mL

98-24-19 4
ATESHKADI ARASH
M / A 03/21/1968

#Mononuclear cells = 1.3×10^8
#Total CD34+ = 2.8×10^6 ~2.2%
Stored mononuclear cells O/N @ 4°C in 50% FCS

Isolated CD34+ from mononuclear cells today
Labeled → Ran through the column.
Total CD34 count = 3.8×10^6 cells
Stored @ 4°C O/N in 50% FCS → Sort G_0/G_1 tomorrow!

: G_0/G_1 Sort: Hairy 80 mg [I] of Hoechst/Pyronin as usual.



performed CD34+ CD38- Ab stain on cells sorted in Region 1 and Region 2.





Sort problems:

The cells gated for Region 1, & 3 ~~were~~ shifted out → ∴ the cells analyzed were not the entire population.

CD34+CD38- Analysis.

Although there seems to be 2 diff. pop. of cells... I expected more

Donor/(Week#) **Ateshkadi, A. 6/11**	*(+)MP*	*(-)MP*	*% +MP*	*IP (<3)*	*IP (>3)*	*(-)IP*	*% +IP (<3)*	*% +IP (>3)*
CYTOKINES								
AA G0 CsCl (4)	2	22	**8.3**	39	37	206	**13.8**	**13.1**
AA G0 CsCl (6)	6	32	**15.8**	15	39	198	**6.0**	**15.5**
AA G0 CsCl (8)	4	28	**12.5**	20	35	200	**7.8**	**13.7**

80°c 2hr
ffer @ 42°c for 5 hr
p 75 λ (0.15 ug)

Volume Total Counts cpm
50 112x10^6

fer w/in 2 blots

* Wash blot from
65°c 2 x 15' 0.5XSSC, 0.1% SDS

* Precipitate down PCR products (and)
-70°c 1 ul glycogen / sample

* Run hot PCR products ( ) on 5% Urea/polyacrylamide Gel

A, A G0 5 wk LTC-IC

No DNA | unTd 1 2 3 | Td CsCl 7 8 9 10 11 12 13 14 15 16 | αPAP 6 copy

No. 1

HIV

400 cells

β-globin

A, A G0 5 wk LTC-IC

No DNA | unTd 4 5 6 | Td CsCl 17 18 19 20 21 22 23 24 25 26 | αPAP 6 copy

No. 2

HIV



400 cells

β-globin

A, A G1 5 wk LTC-IC

No DNA | unTd 1 | Td CsCl 2 3 4 5 6 7 8 9 10 | αPAP 6 copy

No. 3

HIV



400 cells

β-globin

load 1/3 of HIV, 1/2 of β-globin, 1/5 of positive control

400 V
80°c dry 2 hr

* Pick up colonies

MERCADO, ORFEDALIA ( )

5wk LTC-IC CD34+CD38- (

count colonies: unTd 157 (all CFU-GM except 9 E

Td 762 (all CFU-GM except 61 BF

All colonies are big and nice.

pick up colonies:

red colony.



Mature BFU-E (Day 10)

(3-8 multi-clustered)



Primitive BFU-E (Day 18)

~~(9 or more multi-clustered)~~

For PCR: unTd: 1-4 (1-2: CFU-GM

3-4: BFU-E)

Td: 5-24 (5-21: CFU-GM

22-24: BFU-E)

For 2PCR: unTd: 25 (CFU-GM)

Td: 26-34 (26-32: CFU-G

33-34: BFU-E

150ul STE, 0.5 ul RNAse-DNAse 37°C 1

3.75 ul 20% SDS, 2.5 ul PK (10mg/ml) 37°C,

* Run hot PCR products ( ) on 6% Urea/Polyacrylamide Gel.

A, A GO 8wk LTC-IC



( )

38+ CD38− (2

all CFu-Gm except 9 BFu-E

1 CFu-Gm except 61 BFu-E

fig and rice.

1-4 (1-2: CFu-GM
3-4: BFu-E)

5-24 (5-21: CFu-GM
22-24: BFu-E)

25 (CFu-Gm)

26-34 (26-32: CFu-GM
33-34: BFu-E)

ul RNAse - DNAse 37°c 1 hr

2.5 ul PK (10mg/ml) 37°c O/N

6% Urea/Polyacrylamide



A,A Go 8wk LTC-2c



A,A G1 8 wk LTC-2c



load 1/3

load 1/5

400 V

8°c day 2 hr

153</pre>

pick up colony : G0 : un 1-4 (CFU-Gm)
Td 5-24
G1 : un 1-3 (CFU-Gm)
4 (cluster on stroma)
Td 5 (colony - cluster CFU-Gm)
6-7 (cluster floating)
8-15 (cluster lonely on stroma)

150 µl STE, 0.5 µl RNase-DNase free 37°C 1 hr
3.75 µl 20% SDS, 2.5 µl PK (10 mg/ml) 37°C O/N

& Run hot PCR products) on 5% Urea/Polyacrylamide Gel

A,A G0 12 wk LTC-IC



A,A G1 12 wk LTC-IC



load 1/3

dry 80°C 2 hr

i0/G1

G0/G1

c, ½ back to culture
to me

13/716/GmCSF/SCF
25ng/ml
Epo IU/ml

37°C

1
G0/G1 ( )
2 wk, no colony)
(7 nice colony, 2 cluster CFU-Gm
on stroma)
25 (nice colony) CFU-Gm
17 (cluster on stroma or
loose in media)
4 (nice colony) CFU-Gm
5 (cluster on stroma
16 (cluster on stroma or
floating)

Hybridized Probe on FISH slides were detected.



	+ IP	- IP	% IP
Td Harvested:	24	110	18%
	25	80	23%
	17	117	13%
	4	48	8%
	4	49	8%
	0	16	0%
	0	12	0%

Dropped slides of G0 CCL (G0 CA
G1 CA
stored @ -20°C.
patients: Billy, V (VB)
Bravo, J (JB)

Ran antisense HIV PCR product on Midi gel 0.8%
Performed Southern Blot.

Split 293 and made 4 35mm plates for titering
my dPAP CCL vector.



Qiagen of GFP plasmid.
PPT o/N.
loaded a 100ml culture into one column!
→ overloaded column!
therefore lost a lot of plasmid.

Hybridized probe to G_0/G_1 slides.

Resuspended GFP plasmid pellet in TE.
Quantitated
Yield only 60ug/ml.
Therefore only a total of 60 ug!
But SC still could get 4 plates out of my 60ug.

Went to FISH lab to detect probe.

Experiment #2: FISH

Objective: Determine if aPAP vector actually integrated into genome of transduced CD34+ cells residing in G0.

Results:

	+MP	-MP	% MP	+IP	-IP	% IP
VB *Untd G0*	-	-	<1%	-	-	<1%
VB (D35) *G0-CCL*	3	19	14%	30	301	9%
VB (D35) *G0-CCL*	4	29	12%	22	210	9%
VB (D35) *G1-CCL*	-	-	N.D.	-	-	N.D.
JB (D23) *G0-CCL*	5	29	15%	24	232	9%
JB (D23) *G0-CCL*	5	21	19%	13	82	14%
JB (D23) *G1-CCL*	4	24	14%	22	178	11%

Detected probe on FISH slide.

Results:

	+MP	-MP	%MP	+IP	-IP	%IP
Untd G_0 (VB)			0%			0%
Td G_0 cell (VB)	2	20	9%	22	145	13%
Td G_0 CELL (VB)	1	11	8%	25	107	19%
Td G_0 CELL (VB)	1	14	7%	17	105	14%
Td G_0 CELL (VB)	1	15	6%	14	91	13%

Made up MC culture media:
Total Volume = 10mL
IMDM 8mL
20% FCS 2mL
IL3 10ng/mL 10 µl
GMCSF 50ng/mL 2 µl

Prehybridized Blot.

Performed Cindy's MC colony: Halofeed C Oncide 2
→ LTC-IC please

Trypsin-EDTA: Each 15mL tube, prealded 5mL IMDM + 0.5mL FCS. Removed media in well and placed into tube. Then 0.2mL Trypsin was added & let sit for 1min 15sec. Added 1.5mL media from 15mL tube to rinse the well. Repeated one more time to clean the well as good as possible. Then added 2mL fresh plain IMDM to rinse well.

GOCD34+fish.xls

Patient	G0? G1?	Weeks Post Transduction	% +ive MP	% +iv IP (<3)	Comments
Billy, V.	G0	4	9% (2/20)	13% (22/145)	VB Td on
Billy, V.	G0	4	8% (1/11)	19% (25/107)	
Billy, V.	G0	5	14% (3/19)	9% (30/301)	
Billy, V.	G0	5	12% (4/29)	9% (22/210)	
Billy, V.	G1	5	N.D.	N.D.	No metaphase spreads
Billy, V.	G0	6	7% (1/14)	7% (8/105)	
Billy, V.	G0	6	6% (1/15)	9% (9/91)	
Bravo, J.	G0	3	15% (5/29)	9% (24/232)	JB Td on
Bravo, J.	G0	3	19% (5/21)	11% (12/112)	
Bravo, J.	G0	3	18% (4/18)	11% (19/150)	
Bravo, J.	G1	3	14% (4/24)	11% (33/178)	
Bravo, J.	G1	3	16% (3/16)	7% (12/170)	
Bravo, J.	G0	4	10% (3/26)	12% (24/170)	
Bravo, J.	G0	4	14% (4/25)	10% (21/184)	

Pelleted Qiagen prep
Washed w/ 70% EtOH
Resuspended in a total of 1mL TE
(a 100mL culture!)
Quantitated by spec.
[] = 0.520 ug/uL. ∴ total = 520 ug

Pelleted 293 genomic DNA. in microcentrifuge
@ 15,000 RPM for 40 min.
Washed w/ 70% EtOH
Resuspended in 100 λ of TE
Heated sample to allow for better suspension
Quantitated by spec.
[] = 1 ug/uL ∴ Total = 100 ug
260/280 = 1.74

Also Hybridized probe to FISH slides G./G.
(and one Frias, Francisco slide)
Allowed for hybridization O/N @ 37°C in
tissue culture incubator.

Pelleted FISH probe (stored @ -70°C. over my
vacation).
Washed w/ 70% EtOH
Dried and Resuspended in a total of
15λ.
Stored @ -20°C.

Detached Protocol on CD34+ Go slides.

Results:

	+MP	−MP	%-MP <1%	+IP	−IP	%-IP <4%
All Patient JB						
Untd Go.						
Go ca ( )	3	26	10%	24	170	12%
Go ca ( )	4	18	18%	19	150	11%
Go ca ( )	4	25	14%	21	184	10%
Go ca ( )	3	16	16%	12	170	7%
Gi ca ( )	5	20	20%	19	181	9.5%
Fraq F						

→ Colcemid Blocked FISH boosted culture.

Set up another dsense PCR w/ newly extracted 293 DNA.

Genomic @ 100ng/µl		x12
10X Buffer	2.5µl	30µl
DIASP @ 10um	.625µl	7.5µl
RPCP @ 10um	.625µl	7.5µl
dNTP @ 2.5mM	2µl	24µl
Taq	.25µl	3µl
MgCl2 @ 25mM	2µl	24µl
dH2O	16µl	192µl

Total Rxn = 25µl

Set Program @ 98° 5'
80° 1'
94° 40" } 30 cycles
64° 40" }
72° 1'
72° 5'
4° 2 hrs.


TD G0 CD34+ BONE MARROW


UNTD G0 CD34+ BONE MARROW

Bone Marrow today!

Patient:

97-32-31 4
GILLIARD, JEANNETTE
F / W 05/19/1964
Clarisha

Good Yield!!! of CD34+.

Total Volume: 20 mL
→ 2mL for Lu Jiao
~ 18mL for Isolation of CD34+.
Count on Mononuclear Cells = 250,000,000 cells.
Count of Total CD34+ = 3 x 10^6 cells.
Stored @ 4° in 50% FCS / 50% IMDM.
→ will select for Go/G1 tomorrow!

Made new concentration batch of HST + Pyronin Stain.
Stained as usual.
FACS sort Go/G1 populations.



FACS

30,000 cells each sample
CSA (pooled SCA LL) 3cc each well.

Sc asked me to calculate % CD34+ from mononuclear cells from donor to donor.

Patient	Volume BM	# Mononuclear	# Total CD34+	% CD34+
Valentino	15ml	1.00E+08	1.60E+06	1.6
Bravo	44ml	4.00E+08	4.30E+06	1.075
Meiser	38ml	2.80E+08	2.50E+06	0.892857
Alexander	30ml	2.00E+08	2.80E+06	1.4
Kanata	50ml	2.70E+08	3.30E+06	1.222222
Thompson	40ml	2.50E+08	3.40E+06	1.36
Gilliard	18ml	2.50E+08	3.00E+06	1.2

∴ Approx. 1% CD34+

FACS analysis of CD34+CD38- pop. in the G0/G1 CD34+ cells sorted on (patient: Gilliard, Jeannette).
Washed aliquoted cells in ~ 1ml of FACS Buffer.
FACS Buffer: PBS + 0.1% Sodium azide
+2% FCS
Diluted Ab 4:1 in 1ml media. CD34+/CD38- (Becton Dickinson)



Status: Panel

EVENTS: 40276 counts
TIME: 129 secs
RATE: 312/sec
SOURCE: SACAPR17.003
MODE: Free Run
PROTOCOL: FITCPE.SAC
LISTMODE: <none>
SAMPLE: G1 CD34/38
EXPERIMENT: CD34/38 Staining

Stats: PE: M1 vs FITC: G1 : SACAP

Region	Counts	%
1	161	0.42
2	358	0.93
3	37792	98.30
4	136	0.35



Status: Panel

EVENTS: 40521 counts
TIME: 157 secs
RATE: 253/sec
SOURCE: MOFLO
MODE: Listmode 50000
PROTOCOL: FITCPE.SAC
LISTMODE: 1\SACAPR17.001
SAMPLE: G0 CD34/38
EXPERIMENT: CD34/38 Staining

Stats: PE: M1 vs FITC: G1 : SACAP

Region	Counts	%
1	1757	4.66
2	1062	2.82
3	7386	19.60
4	27479	72.92

Washed + fix CD34+ cells Patient: Alexander, Tracy
→ Replated & replaced @ 37°C

FISH Boosted Total CD34+ (1wk well)

Colcemid Boosted CD34+ CM (G0/G1)

Dropped CM slides (3wk) → G0/G1
Could not Harvest Encapsidations Today!!!
→ CPE not up to 50% yet.

Harvested Encapsidations.
2 tubes (5 plates/tube)
Proceeded w/ Protocol as described by [illegible] / [illegible]
After adding FCS, stored @ -80°C

Dropped TM slides (1wk) → Total CD34+

Hybridized λPAP probe to 2week/4week G0 CD34+
Patient: Meber, Cynthia





# of cd34+ cell = 2.5million
gave 500,000 to priscilla.
Stored @ 4° in 50% Iscove / 50% FCS o/N.

Stained CD34+ w/ Hrechst & Pyronin.
(Before staining aliquoted 80,000 out to total CD34+ cells)



Empty 80,000 G_0 100,000 G_1
MC 70,000 G_0 70,000 G_1

Set up my wells as follows:

plate 1:





FACS sort G_0/G_1 populations after staining w/ Hoechst-Pyronin

After sort,

$G_0 = 144,575$

$G_1 = 163,326$

Divided cells among Cindy and I.

Cindy	80,000 G_0	100,000 G_1
Me	70,000 G_0	70,000 G_1

Set up my wells as follows:

plate 1:



plate 2:



(5λ)
nd shield.

Vector Processing

Resuspended cell pellet in 10mL pH8 Tris
Froze/Thawed 2x → Next 2x more.
Sonicated 6x @ 30sec.
Adjusted pH of the stock to 8-8.5 using sterile 1M Tris pH9.5.
Volume of lysate = 11mL
Added 1M MgCl2 → final 1mM = 11λ
Added 4.5λ Benzonase 60'
4.5λ Benzonase another 60'
Added 1.1mL 10X trypsin → 1X
Added 1.1mL DOC 10% → 1%
Vortexed.
Incubated @ 37°C for 30'
Sonicated.
Added ~6.8g CsCl
Adjusted RI to 1.4 (density).
Loaded onto centrifuge w/ CL, Lai(2), SC, SC pooled & mine!!!
Will harvest

Donor: Mercado, O.
CD34+CD38- cells...
Transduced on 7.8.98
CN5/96 CsCl dPAP
FISH HARVEST:
Week 4:
Week 6
Week 8

30λ (90,000 cells.

EROS
15E+07
14.34

Vector checked centrifuge ok ✓

Bone Marrow Today!
Cindy isolated CD34+ ~8x10^6 cells!
Patient : Mercado, Orfedalia 98-20-16-5
F/W 03/22/1970

BFRB
uL
480
480
480

CD34/CD38- Sort.
Resuspended FACS Buffer
Diluted 50λ Ab → 75λ FACS
Mixed into same tube.
Incubated on ice for 45'
Washed w/ 2.5mL FACS
TR w/ CN 5/98 CsCl v



 G0/G1 analysis of CD34+CD38- population.



→ Definitely 2 different cell populations - 98% of all CD34+CD38- cells are in G0!!!

Gradient ... ,cw

Bisonate worked too well???



Density is quite high!!!

VECTOR	CWRAPAP		
HARVESTED	7/9/98		
FRACTION	RI	DENSITY	COMMENT
1	1.3576	1.2463	TOP
2	1.3586	1.2571	
3	1.3615	1.2886	
4	1.363	1.3049	
5	1.365	1.3268	
6	1.3674	1.3527	
7	1.377	1.4570	Vector Band
8	1.3771	1.4580	Vector Band
9	1.3775	1.4624	Vector Band
10	1.3725	1.4081	
11	1.386	1.5547	
12	1.3906	1.6047	

Bone marrow Today!

Patient:

98-29-18 5
LEROS, RICARDO
M / W 12/20/1976

Christine